Barinthus Biotherapeutics (BRNS) Accumulated Expenses (2020 - 2026)

Barinthus Biotherapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 20.66% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.7 million (up 20.66% YoY), and the FY2025 full-year result was $6.2 million, down 34.39% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $8.7 million, up from $6.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.9 million in Q3 2023, with the low at $9000.0 in Q2 2022.
• Historically, Accumulated Expenses has averaged $7.1 million across 5 years, with a median of $8.0 million in 2024.
• The largest YoY upside for Accumulated Expenses was 9335.83% in 2022 against a maximum downside of 92.24% in 2022.
• Barinthus Biotherapeutics' Accumulated Expenses stood at $8.1 million in 2022, then climbed by 14.28% to $9.2 million in 2023, then increased by 3.4% to $9.5 million in 2024, then sank by 34.39% to $6.2 million in 2025, then surged by 38.98% to $8.7 million in 2026.
• The last three Accumulated Expenses figures came in at $8.7 million (Q1 2026), $6.2 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.